Prostate cancer (PCa) is the most common internal malignancy in U.S. men. Most cases of PCa are curable if treated while localized to the prostate. Recent advancements in PCa imaging (MRI, Micro-ultrasound and PSMA PET) are able to accurately localize cancers within the prostate. Because PCa is overall a slow growing cancer, focal therapy where the cancer is destroyed, but other critical structures left undamaged is a reasonable strategy. The decreased cancer control is balanced against improved quality of life when comparing focal therapy to gold standard treatment such as surgery and radiation.
Ideal candidates for focal therapy:
- Greater than 10 years life expectancy
- Intermediate risk prostate cancer
- Small cancer volume
- Ability to achieve an adequate margin without damaging critical structures
- Patient compliance with surveillance
At the University of Florida, we offer focal therapy in the context of clinical trials so patients can be assured they are receiving high quality care while improving the care of the next generation of prostate cancer patients. Our approach focuses on accurately delineating tumor border with multi-modal imaging and planning biopsy.
The above images demonstrate a tumor imaged with 3 separate imaging modalities enabling us to carefully delineate the tumor margins prior to treatment.
Following focal therapy, men will need to be surveyed for tumor reoccurrence, with approximately 20% of men needing additional treatment within 5 years. In the majority of men, urination and erectile function is maintained.